Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-2.11%

16 alerts

-2.11% News Effect

+2.9% Peak Tracked

-15.0% Trough Tracked

-$9M Valuation Impact

$423M Market Cap

0.2x Rel. Volume

On the day this news was published, SLDB declined 2.11%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.9% during that session. Argus tracked a trough of -15.0% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $423M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU grants: 23,284 RSUs Employees granted: 2 employees Vesting schedule: 4 annual installments +1 more

4 metrics

RSU grants 23,284 RSUs Inducement awards to two newly hired employees

Employees granted 2 employees Recipients of 2024 Inducement Plan RSU awards

Vesting schedule 4 annual installments RSUs vest over four years on each grant anniversary

Inducement plan year 2024 2024 Inducement Stock Incentive Plan used for grants

Market Reality Check

Price: $5.47 Vol: Volume 682,917 is 0.64x t...

low vol

$5.47 Last Close

Volume Volume 682,917 is 0.64x the 20-day average of 1,067,822, indicating quieter trading ahead of this filing. low

Technical Shares at $5.87 are trading above the 200-day MA of $4.90 and about 20% below the 52-week high of $7.37.

Peers on Argus

Peers showed mixed moves: AURA +0.62% and LXRX +0.76%, while DMAC -1.68%, FULC -...

Peers showed mixed moves: AURA +0.62% and LXRX +0.76%, while DMAC -1.68%, FULC -5.54%, and ALMS -4.05%. With no momentum signals or same-day peer headlines, this RSU inducement update appears stock-specific rather than part of a coordinated sector move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical data presentations	Positive	-1.0%	New data on AAV-SLB101 and cardiac gene therapy program at CVCT Forum.
Dec 01	Equity inducement grants	Neutral	-2.1%	Grant of 23,284 RSUs to two new employees under inducement plan.
Dec 01	Regulatory designation	Positive	-4.0%	FDA Rare Pediatric Disease designation for SGT-212 gene therapy program.
Nov 17	Licensing agreement	Positive	+2.4%	Non-exclusive global license for AAV-SLB101 with Andelyn Biosciences.
Nov 11	Investor conferences	Positive	+9.2%	Participation in Jefferies and Piper Sandler healthcare investor conferences.

Pattern Detected

Recent positive clinical and corporate updates have produced mixed reactions, with some strong gains and some selloffs, suggesting investors react selectively to news rather than uniformly rewarding positive developments.

Recent Company History

Over the past month, Solid Biosciences reported several pipeline and corporate milestones. On Nov 3, 2025, an 8-K highlighted positive interim SGT-003 data and a Phase 3 trial start. A Nov 17, 2025 licensing deal expanded access to the AAV-SLB101 capsid. The company also scheduled investor conference appearances on Nov 11, 2025 and announced FDA Rare Pediatric Disease designation for SGT-212 on Dec 1, 2025. Today’s 23,284 RSU inducement grants fit into an ongoing pattern of equity-based compensation and insider-related activity.

Market Pulse Summary

This announcement details inducement grants of 23,284 RSUs to two new employees under the company’s ...

Analysis

This announcement details inducement grants of 23,284 RSUs to two new employees under the company’s 2024 Inducement Stock Incentive Plan, issued in line with Nasdaq Listing Rule 5635(c)(4). It adds incrementally to equity-based compensation already visible in recent Form 4 filings. Investors may track how such awards affect overall share count alongside previously disclosed capital raises and monitor upcoming clinical and corporate milestones referenced in recent 8‑K and 10‑Q filings for more fundamental drivers.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

4 terms

restricted stock units financial

"announced grants of 23,284 restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"restricted stock units (“RSUs”) to two newly hired employees"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company’s 2024 Inducement Stock Incentive Plan"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. Not financial advice.

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 23,284 restricted stock units (“RSUs”) to two newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

What did Solid Biosciences (SLDB) announce on December 1, 2025 about employee equity?

The company granted 23,284 RSUs to two newly hired employees as inducement awards under its 2024 Inducement Stock Incentive Plan.

How do the RSUs granted by SLDB vest and what is the timeline?

The RSUs vest in four equal annual installments, on each one-year anniversary of the grant date through year four, subject to continued service.

Under which plan and Nasdaq rule were the Solid Biosciences RSUs granted?

The grants were made under the 2024 Inducement Stock Incentive Plan as inducements consistent with Nasdaq Listing Rule 5635(c)(4).

How many employees received RSUs in the Solid Biosciences December 1, 2025 grant?

Two newly hired employees received the total award of 23,284 RSUs.

Are the RSU awards from SLDB conditional or guaranteed?

Vesting of the RSUs is conditional on each employee's continued service with the company through each vesting date.